Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.40 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909437 | 1.00 | ALDH1A1 (0.60) | ALDH1A1PIK3CDPOLBTDP1IDO1 | |
| SCHEMBL18863410 | 0.83 | PIK3CD (0.43) | ALDH1A1PIK3CDMAPTMEN1KMT2A | |
| SCHEMBL26878892 | 0.81 | ALDH1A1 (0.62) | ALDH1A1POLBIDO1MAPTNPSR1 | |
| SCHEMBL31053163 | 0.79 | ALDH1A1 (0.60) | ALDH1A1POLBTDP1IDO1RORC | |
| SCHEMBL909398 | 0.79 | ALDH1A1 (0.60) | ALDH1A1POLBIDO1MAPTNPSR1 | |
| SCHEMBL25299377 | 0.79 | ALDH1A1 (0.60) | ALDH1A1POLBIDO1MAPTNPSR1 | |
| SCHEMBL3650139 | 0.79 | ALDH1A1 (0.60) | ALDH1A1POLBIDO1CYP3A4MAPT | |
| SCHEMBL30517139 | 0.79 | ALDH1A1 (0.60) | ALDH1A1POLBIDO1MAPTNPSR1 | |
| SCHEMBL20569282 | 0.79 | ALDH1A1 (0.65) | ALDH1A1POLBIDO1TSHRMAPT | |
| SCHEMBL1278657 | 0.79 | ALDH1A1 (0.60) | ALDH1A1POLBTDP1IDO1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| EP-4458819-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118451068-A | Tri-fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118420620-A | Heterocyclic compounds | 武田药品工业株式会社 | 2024-08-02 | — | — | CN | disclosed |
| CN-113038948-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-117120442-A | Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117120427-A | MALT1 inhibitor and preparation method and application thereof | 上海拓界生物医药科技有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116507607-A | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023125877-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4163280-A1 | METHOD FOR PRODUCING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2023-04-12 | — | — | EP | disclosed |
| CN-112601747-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | ALDH1A1 792/4885PIK3CD 1455/4885POLB 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.